Credit Suisse Securities (USA) LLC acted as the sole book-running manager for the offering. Piper Jaffray & Co., Leerink Swann LLC, and Allen & Company LLC acted as co-managers.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 31, 2007. This offering is being made solely by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from Credit Suisse, Prospectus Department, One Madison Avenue, Level 1B, New York, NY 10010 (telephone number: (212) 325-2580).
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Nanosphere, Inc.
Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene(r) System for direct genomic and ultra-sensitive protein detection. This easy to use and cost effective platform enables simple, low cost and highly sensitive genomic and protein testing on a single platform. Nanosphere is based in Northbrook, IL. Additional information is available at http://www.nanosphere.us.
The Nanosphere, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4344
Contact: Schwartz Communications, Inc. Laura Kempke Andrea tenBroek 781-684-0770 nanosphere@schwartz-pr.com
Source: Nanosphere, Inc.
